Eligibility is built around two main pieces of information: your BMI and whether you have any weight-related comorbidities
Within controlled research environments, GHK-Cu remains a compound of interest in studies exploring connective tissue biology, collagen-related mechanisms, and cellular response pathways
We now have top line phase 3 data for retatrutide a triple (GIP, GLP-1, glucagon) agonist: At 40 weeks (efficacy estimand): ~16.8% weight loss ~1.9% A1c reduction We are entering a new phase: Multi-hormonal therapies Integrated obesity and diabetes care Precision approaches to cardiometabolic disease One pathway is not enough for a complex disease like obesity, and it is exciting to see a growing pipeline of therapies with distinct mechanisms
Most patients can safely resume tirzepatide 24 weeks after surgery, depending on the procedure type and surgeon approval
Lipoxins may have a regulatory role in the immune response to infection by parasitic pathogens, such as Toxoplasma gondii and Mycobacterium tuberculosis
Treatment trusted by thousands Phoenix families are reclaiming their health and vitality through medically supervised weight loss programs happening right now